IMMP under halt: what may really be behind it ( $IMMP )

Immutep’s Nasdaq-listed ADRs were halted on Friday, March 6, 2026 under code T1 / News Pending. On the Australian side, the public halt notice points to an announcement regarding the outcome of the pre-specified interim futility analysis for the Phase III TACTI-004 trial. That single detail matters a lot: it shifts the center of gravity from wild speculation to a very specific clinical event. What follows is a structured look at the facts, the company, the pipeline, and the full range of plausible scenarios.

Weekly Recap & Briefing – Oil Shock, Weak Jobs, Iran War and a More Selective Tape (Mar 2–6, 2026)

The week that closed on Friday 6 March was the first full trading week in which markets had to process the new Middle East war regime rather than just react to a weekend headline. The U.S.–Israeli campaign against Iran and the retaliation that followed kept energy, shipping and inflation risk at the centre of the tape, while the S&P 500 ended the week lower, the VIX climbed to its highest level since April 2025 and Brent crude pushed above 90 dollars a barrel. On top of that, Friday’s U.S. jobs report added a second layer of stress: payrolls unexpectedly fell and the unemployment rate moved up, pushing investors into an awkward mix of growth fear and inflation fear at the same time.

PMV Pharmaceuticals Inc ( $PMVP )

PMV Pharmaceuticals is a precision oncology company built around rezatapopt (PC14586), an oral small-molecule reactivator of p53 designed for tumors harboring the TP53 Y220C mutation. The story matters because TP53 is one of the most important tumor suppressor genes in cancer biology, and because PMV has now moved from mechanism-only interest into clinically visible efficacy data. The company’s registrational PYNNACLE study has produced an overall 34% ORR across evaluable Phase 2 patients and a 46% ORR in the ovarian cohort at the September 4, 2025 cutoff, with the company later reporting a 50% ORR in the same ovarian cohort after that cutoff. FDA Orphan Drug Designation granted on March 2, 2026 adds meaningful regulatory support. PMV says it plans to submit an NDA in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation.

Obesity Medicines 2026 — Part 1: sector map for investors

A stock-market overview built around the names that matter most in the public conversation today: Novo Nordisk (NVO), Eli Lilly (LLY), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), Altimmune (ALT), Fractyl Health (GUTS) and Zealand Pharma (ZEAL). This first part is not a medical explainer. It is a market map: who already has real commercial power, who is still trying to earn strategic relevance, and which catalysts actually matter for the shares.

Obesity Medicines 2026 Part 2

Part 2 moves from the sector to the stocks themselves. Each company is examined through the same lens: ticker, core asset, stage, regulatory standing, commercial position, why the market cares, bull case, bear case and the next likely stock-moving issues. The goal is not to crown a winner but to show what each public name really is today.

Rumble Inc ( $RUM )

Executive summary
Rumble is no longer just a politically differentiated video platform. After FY 2025 results, the company is trying to present itself as a three-layer story: a creator and media platform, an advertising and subscription monetization engine, and a cloud / GPU infrastructure business that could become much more material if the Northern Data transaction closes.

The War Economy

The market is no longer treating Middle East escalation as a passing geopolitical shock. It is increasingly pricing it as a broader economic regime: one that reprices oil and LNG, lifts defense and dual-use space names, pressures airlines and small caps, and forces investors to rethink the physical vulnerability of cloud infrastructure

Three March PDUFAs retail biotech traders are watching most closely

March is packed with biotech catalysts, but for many retail traders the shortlist comes down to three names: Lantheus, Aldeyra and Rocket Pharmaceuticals. They are very different stories — one radiopharma platform name, one dry-eye binary, one rare-disease gene-therapy approval setup — but all three have the ability to move fast around FDA timing, market expectations and headline interpretation.

Horizon Aircraft Ltd ( $Hovr ) lower-cost VTOL pitch gets sharper

Horizon Aircraft’s latest update was not about a signed order or a certification milestone. It was a commercial positioning update: management is now leaning harder on the argument that the Cavorite X7 could operate at materially lower cost than helicopters, while continuing a visible March–April industry-events circuit to keep the platform in front of operators, investors and policy stakeholders.

Planet Labs ( $PL ) Europe, defence and sovereign satellite demand

Planet is no longer a simple “satellite imagery story” to be judged on a vague promise of future demand. The company now sits at the intersection of recurring Earth-data subscriptions, defence and intelligence workflows, sovereign demand for dedicated capability, and a broader European push toward strategic autonomy in space and geospatial data. The stock has already been re-rated hard, so the real question is no longer whether Planet has become more relevant. It clearly has. The real question is whether this growing strategic relevance can convert into cleaner revenue quality, stronger margins, and a more durable case into the next earnings event.

Zeta Global Holdings Corp ( $ZETA )

Zeta Global ended 2025 with roughly $1.3 billion in revenue, high-20s growth, expanding margins and a still-modest GAAP net loss, while launching a strategic collaboration with OpenAI to power Athena, its enterprise AI marketing agent. The investment case now revolves less around “can they grow” and more around “can they sustain growth, expand margins and prove that their data and AI stack is truly differentiated.

SeaStar Medical Holding Corp ( $ICU )

SeaStar Medical announced completion of the FDA-mandated enrollment requirement (50 patients) for the SAVE Surveillance Registry evaluating QUELIMMUNE safety in pediatric AKI with sepsis requiring continuous kidney replacement therapy (CKRT).

Atara Biotherapeutics (ATRA): after the new tabelecleucel update, a second attempt at an FDA path 

Two months after the FDA’s complete response letter on tabelecleucel for EBV+ PTLD, Atara and partner Pierre Fabre are back in Washington with a Type A meeting request and a thick briefing book. The goal is simple but ambitious: convince the agency that the data set behind EBVALLO, already approved in Europe, can still support a viable U.S. path despite the sudden change of tone on the ALLELE trial.

Castellum Inc ($CTM) – FY 2025 Results & 2026 Execution

On March 4, 2026, Castellum Inc. announced its unaudited FY 2025 financial results, and the numbers reveal a company that has fundamentally shifted trajectory. After years of acquisition-driven roll-up activity, balance sheet stress, and constant capital raises, CTM is now reporting organic revenue growth, positive adjusted EBITDA, and—perhaps most significantly—has completely eliminated all outstanding debt. This is not a dramatic overnight turnaround; rather, it is the culmination of methodical execution: progressive debt paydown, operational efficiency improvements, successful Navy contract wins, and a disciplined capital allocation strategy that prioritizes sustainability over growth-at-any-cost.